CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $16.41M, lower than 95% of all stocks globally
- PositionGross margin is -81.8%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.97BCNY292.22M · vs all stocks (USD)
Revenue (TTM)
110.32MCNY16.41M · vs all stocks (USD)
Profit Margin
-166.13%vs Biotechnology peers
Beta
0.2540xvs all stocks
52-Week Change
-4.72%vs all stocks
Market Capitalization
1.97BCNY292.22M · vs all stocks (USD)
Enterprise Value
2.10BCNY312.09M · vs all stocks (USD)
Price to Sales (TTM)
19.47xvs Biotechnology peers
Price to Book (MRQ)
1.99xvs Biotechnology peers
Enterprise to Revenue
19.02xvs Biotechnology peers
Enterprise to EBITDA
-13.02xvs Biotechnology peers
Gross Margin
-81.81%vs Biotechnology peers
Profit Margin
-166.13%vs Biotechnology peers
Operating Margin
-2533.10%vs Biotechnology peers
Return on Assets (TTM)
-8.27%vs Biotechnology peers
Return on Equity (TTM)
-15.69%vs Biotechnology peers
Revenue (TTM)
110.32MCNY16.41M · vs all stocks (USD)
Revenue per Share (TTM)
0.8990CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-74.10%vs Biotechnology peers
Gross Profit (TTM)
49.94MCNY7.43M · vs all stocks (USD)
EBITDA (TTM)
-161.24MCNY-23.98M · vs all stocks (USD)
Net Income (TTM)
-183.27MCNY-27.25M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-97.86%vs Biotechnology peers
Operating Cash Flow (TTM)
-151.57MCNY-22.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.40MCNY-3.18M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
112.88MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
40.22MCNYFY2025 · Dec 31, 2025Gross Profit
72.67MCNYFY2025 · Dec 31, 2025Operating Income
-169.72MCNY-25.24M · vs all stocks (USD)
Pre-tax Income
-197.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
-18.75MCNYFY2025 · Dec 31, 2025Net Income
-178.46MCNYFY2025 · Dec 31, 2025EBIT
-195.94MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-132.27MCNYFY2025 · Dec 31, 2025Research & Development
91.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
100.95MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
369.96KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.28MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.45CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.45CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
123.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
123.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-178.46MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-223.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
-258.60MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.19MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-178.46MCNYFY2025 · Dec 31, 2025Other Non-cash Items
1.87MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-29.72MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.32MCNYFY2025 · Dec 31, 2025Capital Expenditures
-34.97MCNYFY2025 · Dec 31, 2025Sale of Investments
5.25MCNYFY2025 · Dec 31, 2025Other Investing Activity
163.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
133.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
103.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-52.60MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.26MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
49.14MCNYFY2025 · Dec 31, 2025Shares Outstanding
123.20MSharesUpdated Aug 21, 2026Float Shares
36.48MSharesUpdated Aug 21, 2026% Held by Insiders
75.00%vs all stocks
% Held by Institutions
0.26%vs all stocks
Total Cash (MRQ)
148.77MCNY22.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.21CNYUpdated Aug 21, 2026Total Debt (MRQ)
100.07MCNY14.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0929xvs Biotechnology peers
Current Ratio (MRQ)
1.52xvs Biotechnology peers
Book Value per Share (MRQ)
8.74CNYUpdated Aug 21, 2026Total Assets
1.42BCNY210.96M · vs all stocks (USD)
Total Current Assets
355.66MCNYFY2025 · Dec 31, 2025Total Liabilities
319.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.06BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
77.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
241.66MCNYFY2025 · Dec 31, 2025Cash
84.19MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.19MCNYFY2025 · Dec 31, 2025Other Short-term Investments
109.05MCNYFY2025 · Dec 31, 2025Accounts Receivable
139.74MCNYFY2025 · Dec 31, 2025Inventory
16.33MCNYFY2025 · Dec 31, 2025Accounts Payable
77.90MCNYFY2025 · Dec 31, 2025Short-term Debt
70.05MCNYFY2025 · Dec 31, 2025Long-term Debt
28.01MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
123.20MCNYFY2025 · Dec 31, 2025Retained Earnings
-166.72MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.10BCNY163.45M · vs all stocks (USD)
52-Week Low
12.50CNYUpdated Aug 21, 202652-Week High
31.20CNYUpdated Aug 21, 202652-Week Change
-4.72%vs all stocks
Beta
0.2540xvs all stocks
50-Day MA
14.92CNYUpdated Aug 21, 2026200-Day MA
18.93CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.97MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.83MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.49CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -81.8%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.82Industry median: 0.67Industry P5: 0.14Peers compared: 261
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 19.47Revenue Growth YoY: -0.74
Financial Health
Altman Z-Score 3.25: safe zoneNotable
Altman Z-Score: 3.25
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $16.41M, lower than 95% of all stocks globallySignificant
Revenue (USD): 16,405,393.349Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Hile Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule